<prompt> First line treatment of T315I mutation in CML management is?BosutinibTofacitinibPonatinibNilotinib  <response>: T315I mutation is a mutation in the critical BCR-ABL kinase in the ATP-binding pocket This prevents imatinib binding and hence leads to resistance to imatinib, nilotinib, bosutinib, and dasatinib. Only drug effective for T315I mutation CML Ponatinib. Otherwise DOC CML Imatinib. DOC for Imatinib resistant CML Bosutinib DOC in case of failure of 2 Tyrosine kinase inhibitor OMACETAXINE 